Noticias y vídeos - RIGEL PHARMACEUTICALS INC.

Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update PR Newswire SOUTH SAN FRANCISCO, Calif., April 30, 2024 SOUTH SAN FRANCISCO, Calif. , April 30, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2024 financial results after market close on Tuesday, May 7 , 2024. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m....

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., April 10, 2024 SOUTH SAN FRANCISCO, Calif. , April 10, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with...

Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma PR Newswire SOUTH SAN FRANCISCO, Calif., April 4, 2024 Olutasidenib induced durable composite complete remission in 43.8% of patients relapsed or refractory to prior venetoclax-based regimens Safety was consistent with the overall profile of olutasidenib Olutasidenib may offer a valuable treatment option for patients with mIDH1 previously treated with...

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer PR Newswire SOUTH SAN FRANCISCO, Calif., March 12, 2024 SOUTH SAN FRANCISCO, Calif. , March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief Medical Officer. Dr. Rojkjaer is an industry veteran with over 20 years of clinical development, regulatory, and medical affairs experience with a focus on...

Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update PR Newswire SOUTH SAN FRANCISCO, Calif., March 5, 2024 Fourth quarter 2023 Total Revenue of $35.8 million which includes TAVALISSE ® net product sales of $25.7 million and REZLIDHIA ® net product sales of $3.9 million Expanded product portfolio with acquisition of U.S. rights to GAVRETO ® , an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung...

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update PR Newswire SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 SOUTH SAN FRANCISCO, Calif. , Feb. 27, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2023 financial results after market close on Tuesday, March 5 , 2024. Rigel senior management will follow the announcement with a live conference...

Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO® PR Newswire SOUTH SAN FRANCISCO, Calif., Feb. 22, 2024 GAVRETO ® (pralsetinib) is an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer Acquisition of established U.S. marketed product further expands Rigel's portfolio and leverages Rigel's existing infrastructure in both the institutional and community settings GAVRETO generated ~$28M in...

Rigel Pharmaceuticals Provides Business Update PR Newswire SOUTH SAN FRANCISCO, Calif., Jan. 8, 2024 Preliminary fourth quarter 2023 total revenue of approximately $35.7 million which includes record TAVALISSE ® net product sales of $25.7 million and REZLIDHIA ® net product sales of $3.9 million Strategic alliance with MD Anderson to advance REZLIDHIA in AML and other cancers Collaboration with CONNECT to evaluate REZLIDHIA in a Phase 2 clinical trial in glioma SOUTH SAN FRANCISCO, Calif. ,...

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., Jan. 5, 2024 SOUTH SAN FRANCISCO, Calif. , Jan. 5, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ...

Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma PR Newswire SOUTH SAN FRANCISCO, Calif., Jan. 4, 2024 SOUTH SAN FRANCISCO, Calif. , Jan. 4, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a collaboration with CONNECT, an international collaborative network of pediatric cancer centers, to conduct a Phase 2 clinical trial to evaluate REZLIDHIA ® (olutasidenib) in combination with temozolomide as maintenance therapy in...

Rigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif., Jan. 3, 2024 SOUTH SAN FRANCISCO, Calif. , Jan. 3, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and CEO, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 12:00 p.m. PT in San Francisco, CA. To access the live webcast or archived recording,...

Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other Cancers PR Newswire SOUTH SAN FRANCISCO, Calif. and HOUSTON, Dec. 8, 2023 SOUTH SAN FRANCISCO, Calif. and HOUSTON , Dec. 8, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and The University of Texas MD Anderson Cancer Center (MD Anderson) today announced a multi-year strategic development collaboration to expand the evaluation of REZLIDHIA ® (olutasidenib) in...

Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update PR Newswire SOUTH SAN FRANCISCO, Calif., Nov. 7, 2023 Third quarter 2023 Total Revenue of $28.1 million which includes record TAVALISSE ® net product sales of $24.5 million and REZLIDHIA ® net product sales of $2.7 million New data on olutasidenib in mIDH1 relapsed or refractory acute myeloid leukemia to be presented at ASH Annual Meeting Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH...

Rigel to Present at the Jefferies London Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif., Nov. 6, 2023 SOUTH SAN FRANCISCO, Calif. , Nov. 6, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno , the company's chief financial officer, will present a company overview at the Jefferies 2023 London Healthcare Conference on Tuesday, November 14, 2023 at 3:30 p.m. GMT ( 10:30 a.m. EST ). To access the live webcast or archived recording, visit...

Rigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition PR Newswire SOUTH SAN FRANCISCO, Calif., Nov. 2, 2023 -- Growing body of data on REZLIDHIA ® (olutasidenib) in mIDH1 relapsed or refractory (R/R) acute myeloid leukemia (AML) patients -- -- New data on olutasidenib in patients with mIDH1 myelodysplastic syndromes/neoplasms (MDS) -- SOUTH SAN FRANCISCO, Calif. , Nov. 2, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL)...

Rigel Announces Conference Call and Webcast to Report Third Quarter 2023 Financial Results and Business Update PR Newswire SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2023 financial results after market close on Tuesday, November 7 , 2023. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30...

Rigel Announces Presentation at the Upcoming IDWeek 2023 PR Newswire SOUTH SAN FRANCISCO, Calif., Oct. 11, 2023 -- Provides Update on ACTIV-4 Host Tissue Trial -- SOUTH SAN FRANCISCO, Calif. , Oct. 11, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an upcoming oral presentation highlighting data from the FOCUS Phase 3 clinical trial of fostamatinib in hospitalized COVID-19 patients without respiratory failure who have certain high-risk prognostic factors at...

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., Oct. 6, 2023 SOUTH SAN FRANCISCO, Calif. , Oct. 6, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ...

Rigel to Present at the 2023 Cantor Global Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif., Sept. 20, 2023 SOUTH SAN FRANCISCO, Calif. , Sept. 20, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno , the company's chief financial officer, will present a company overview at the Cantor Global Healthcare Conference on Wednesday, September 27, 2023 at 3:35 p.m. ET in New York, NY . To access the live webcast or archived recording, visit...

Rigel to Participate in Upcoming September Investor Conferences PR Newswire SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 SOUTH SAN FRANCISCO, Calif. , Aug. 30, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and chief executive officer, and Dean Schorno , the company's chief financial officer, will participate in the following investor conferences in September: 2023 Wells Fargo Healthcare Conference, September 6-8, 2023...